# Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)

> **NCT00777296** · PHASE1,PHASE2 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 66 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ARIKACE™
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00777296
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-22
- **Primary completion:** 2008-02-27
- **Final completion:** 2008-02-27
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777296, "Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00777296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*